


John C. Lipham, M.D. Professor & Chief of the Division of Upper GI and Gen Surgery, Keck School of Medicine USC. Past President of the American Foregut Society


🔬 Does H. pylori infection influence progression of Barrett’s esophagus? 📊 In our study published in @JournalofGISurg, involving 266,856 patients with nondysplastic Barrett’s esophagus: 📉 H. pylori infection was associated with lower progression to dysplasia or esophageal adenocarcinoma (3.9% vs 8.3%). 🎯 Potential implications for risk stratification. 🔗 doi.org/10.1016/j.gassur.202… @SSATNews @SAGES_Updates @sepdigestiva @CelestinoGutirr @NeilFlochMD @sminaev2015 @stevenbollipo @drkeithsiau @CarlKayMD #BarrettsEsophagus #GERD

🚀 The first RefluxStop® procedures in the United States were performed yesterday by Dr. John Lipham, Chief of the Division of Upper GI and General Surgery, @KECKSchool_USC and Past President of @American_Foregut 🗞️ Read all about it: implantica.com/us/news-event…

What do long-term outcomes reveal about the role of LINX in GERD management? Join us tomorrow at 8 PM ET for “LINX for GERD Management in 2026,” featuring Dr. Christopher DuCoin (@chrisducoin) and Dr. John Lipham (@liphamjohn), moderated by Dr. Tarek Hassab (@TarekHassabMD). Explore expert insights into patient selection, safety, and the long-term evidence surrounding LINX therapy. Don't miss this opportunity to hear directly from experienced surgeons and gain a deeper understanding of the clinical considerations behind LINX. Tune in live! This webinar is sponsored by Johnson & Johnson MedTech (@JNJMedTech). Event Link: share.surgeonapp.com/public/… #SurgeOn #GERD #LINX #GERDManagement #SurgicalEducation

When it comes to GERD treatment, how do surgeons determine which patients are right for LINX? Join us on November 4 at 8 PM ET for “LINX for GERD Management in 2026,” featuring Dr. Christopher DuCoin (@chrisducoin) and Dr. John Lipham (@liphamjohn), moderated by Dr. Tarek Hassab (@TarekHassabMD). Explore expert perspectives on patient selection, safety considerations, and long-term outcomes associated with LINX therapy. Gain valuable insights into the clinical decisions shaping GERD management. Don't miss this expert-led discussion! This webinar is sponsored by Johnson & Johnson MedTech (@JNJMedTech). Event Link: share.surgeonapp.com/public/… #SurgeOn #LINX #GERD #GERDManagement #SurgicalEducation

LINX for GERD: What should surgeons know beyond the procedure itself? Join us on November 4 at 8 PM ET as Dr. Christopher DuCoin (@chrisducoin) and Dr. John Lipham (@liphamjohn), moderated by Dr. Tarek Hassab (@TarekHassabMD), examine the role of LINX in modern GERD management, focusing on patient selection, safety, and long-term clinical outcomes. From evaluating appropriate candidates to understanding long-term results, this discussion brings valuable perspectives to an important surgical topic. Hear directly from experienced surgeons and expand your understanding of LINX therapy. Join the conversation! This webinar is sponsored by Johnson & Johnson MedTech (@JNJMedTech). Event Link: share.surgeonapp.com/public/… #SurgeOn #LINX #GERD #MinimallyInvasiveSurgery #SurgicalEducation

It's the last #ForegutFriday of October, but it's not too late to join the discussion on the Doc Matter AFS community! Discuss clinical cases and ask questions here: zurl.co/5IVh9 #AFS #foregut #foregutcare

Honored to be part of the Inaugural Asian Pacific Foregut Society meeting in Hong Kong!! #AFS #BetterTogether #EFS #JFS #APFS


Read the AFS Journal article 'Enhancing ERAS With Fosaprepitant or Fosaprepitant + Paragastric Autonomic Nerve Blockade' by Iris G. Vallavanatt, Christopher Janssen, Micah Thomas, Monia Yovic, Janelle M. Jakobi, Gabriel Arevalo, and Todd A. Worley. 🔗 zurl.co/c6QD3.

Miffy was born in Utrecht. So was your next congress. 🐰💤 Find ISDE in the Community Area (Hall 6) at UEG Week for a first look at the 23rd ISDE World Congress: Utrecht, Sept 21-23, 2027. #esophagus #ScientificMeeting isde-congress.net/

We're back for another #ForegutFriday. Check out what your peers are discussing this week in the DocMatter AFS community here: zurl.co/ycPRV #AFS #foregut #foregutcare

It's time for another #ForegutFriday! Join the conversation and find out what's happening now in the AFS DocMatter community: zurl.co/K4j13 #AFS #foregut #Foregutcare

Thank you to everyone who attended the 2026 AFS Annual Meeting! It was great to connect with you all. Thank you to all of our incredible speakers, sponsors, and exhibitors for helping make this year's meeting a success. Until next time! #AFS2026

Read the recent AFS Journal article 'Endoscopic Rendezvous Procedure for Complete Esophageal Obstruction' by Kaveh Hajifathalian. 🔗 zurl.co/gAESX. #AFS #foregut #foregutcare

Esophageal cancer claims more American lives each year than melanoma and cervical cancer combined. Yet it receives only a fraction of the public awareness. Too often, it's diagnosed only after symptoms appear, when treatment options are more limited. The goal isn't to detect cancer—it's to find precancer first. Barrett's esophagus—the precancerous condition that can lead to esophageal adenocarcinoma—can be detected, monitored, and treated before cancer develops. EsoGuard® helps make that possible with a non-invasive test for at-risk patients. Awareness is the first step. Early detection is what changes outcomes.